Translating research into licensed vaccines and validated and licensed diagnostic tests.

Area of Science:

• Veterinary Medicine
• Regulatory Science
• Animal Health

Background:

• The Center for Veterinary Biologics (CVB) regulates veterinary biological products in the US.
• Standard licensing requires extensive pre-market evaluation of product safety, potency, and efficacy.
• Emerging or transboundary animal diseases may necessitate rapid product availability beyond standard processes.

Purpose of the Study:

• To discuss the challenges and benefits of obtaining pre-approval for veterinary biological products.
• To explore regulatory pathways for veterinary biologics during animal health emergencies.
• To highlight the importance of proactive product evaluation for future disease outbreaks.

Main Methods:

• Review of existing regulatory frameworks for veterinary biologics.
• Analysis of the standard licensing and permitting process.
• Discussion of alternative pathways for emergency use authorization.
• Consideration of pre-approval strategies for anticipated needs.

Main Results:

• Standard evaluation processes may be insufficient during novel or transboundary animal disease events.
• Existing US processes allow for expedited availability of veterinary products in emergencies.
• Pre-approval offers advantages for ensuring timely access to critical veterinary medicines.
• Challenges exist in balancing rapid approval with comprehensive safety and efficacy evaluations.

Conclusions:

• Proactive strategies for veterinary biologic approval are crucial for effective response to animal health emergencies.
• Pre-licensure evaluation can mitigate risks associated with rapid deployment of products.
• Balancing regulatory rigor with the need for swift action is essential for safeguarding animal health.
• Further discussion is needed on optimizing regulatory pathways for emerging threats.